Spero Therapeutics Strengthens Leadership Team to Advance Immunology Pipeline
Key Highlights
- ➤Amy Rock appointed Chief Regulatory and Quality Officer for SP001 development
- ➤Dae Gon Ha appointed Senior Vice President, Corporate Development
- ➤Timothy Keutzer to retire as Chief Operating Officer December 31, 2026
- ➤Keutzer led Utebzi development through FDA approval and GSK partnership milestones
Expert Statements
Esther Rajavelu, President and Chief Executive Officer of Spero Therapeutics
“These appointments represent another important step to bolster our leadership team, as we execute on Spero's immunology-focused strategy, advancing SP001 and evaluating opportunities to expand our pipeline of therapies for immune-mediated diseases.”
Esther Rajavelu, President and Chief Executive Officer of Spero Therapeutics
“Amy brings a strong track record of navigating complex regulatory pathways for innovative therapies, including biologics, and will be instrumental in shaping an efficient global development strategy for SP001. Dae Gon brings a distinctive combination of scientific expertise and deep knowledge of biopharma markets. Together with the recent appointment of Dr. Debra Zack as Chief Medical Officer, these appointments significantly strengthen our ability to advance SP001 and execute our long-term strategy.”
Esther Rajavelu, President and Chief Executive Officer of Spero Therapeutics
“On behalf of the Board and the entire Spero team, I want to express my deepest appreciation to Tim for his extraordinary dedication and contributions over the past 11 years,”
Esther Rajavelu, President and Chief Executive Officer of Spero Therapeutics
“Tim has been an invaluable partner and trusted colleague throughout some of the most consequential chapters in Spero's history. His leadership was central to the advancement of Utebzi, its successful FDA approval and our partnership with GSK, achievements that have helped establish the foundation for Spero's growth. We are deeply grateful for his lasting contributions to Spero and wish him every happiness in his well-deserved retirement.”
* Amy Rock, Ph.D., appointed Chief Regulatory and Quality Officer, bringing extensive experience in global regulatory strategy, clinical development, and with approvals of novel immunotherapies * Dae Gon Ha, Ph.D., appointed Senior Vice President, Corporate Development, bringing expertise in biopharmaceutical capital markets strategy and business development * Chief Operating Officer Timothy Keutzer to retire after eleven years of leadership and instrumental contributions to Utebzi (tebipenem pivoxil), Spero's legacy program out licensed to GSK CAMBRIDGE, Mass., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases, today announced the appointments of Amy Rock, Ph.D., as Chief Regulatory and Quality Officer and Dae Gon Ha, Ph.D., as Senior Vice President, Corporate Development. The Company also announced that Timothy Keutzer, Chief Operating Officer, will retire from Spero effective December 31, 2026.
Get started
Create a free account to read the full story.